| abstract |
Disclosed is a disintegrin variant that specifically binds one or more of α5β1 and αν integrins such as ανβ1, ανβ3, ανβ5, ανβ6 and ανβ8, but with reduced binding activity to αIIbβ3. Also disclosed are the use of disintegrin variants for the treatment or prevention of diseases associated with αv integrin and α5β1 integrin. |